{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:08:39Z","timestamp":1789538919669,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"DOI":"10.1007\/s00011-025-02170-w","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T13:45:43Z","timestamp":1767879943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of cancer risks associated with JAK inhibitors and TNF inhibitors treatment in patients with rheumatoid arthritis: a systematic review and meta-analysis of real-world cohort studies"],"prefix":"10.1007","volume":"75","author":[{"given":"Fu-Yu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-You","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Cheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsien","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"3","key":"2170_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.31138\/mjr.20230801.oo","volume":"34","author":"M Jahid","year":"2023","unstructured":"Jahid M, et al. Overview of rheumatoid arthritis and scientific understanding of the disease. Mediterr J Rheumatol. 2023;34(3):284\u201391.","journal-title":"Mediterr J Rheumatol"},{"issue":"4","key":"2170_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11914-013-0172-1","volume":"11","author":"ES Clayton","year":"2013","unstructured":"Clayton ES, Hochberg MC. Osteoporosis and osteoarthritis, rheumatoid arthritis and spondylarthropathies. Curr Osteoporos Rep. 2013;11(4):257\u201362.","journal-title":"Curr Osteoporos Rep"},{"issue":"9","key":"2170_CR3","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.3899\/jrheum.110049","volume":"38","author":"N Alaaeddine","year":"2011","unstructured":"Alaaeddine N, et al. CCL20 stimulates proinflammatory mediator synthesis in human fibroblast-like synoviocytes through a MAP kinase-dependent process with transcriptional and posttranscriptional control. J Rheumatol. 2011;38(9):1858\u201365.","journal-title":"J Rheumatol"},{"key":"2170_CR4","doi-asserted-by":"publisher","first-page":"100768","DOI":"10.1016\/j.lanepe.2023.100768","volume":"35","author":"M Beydon","year":"2023","unstructured":"Beydon M, et al. Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study. The Lancet Regional Health. 2023;35:100768.","journal-title":"The Lancet Regional Health"},{"key":"2170_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/oxfordjournals.epirev.a036058","volume":"12","author":"MC Hochberg","year":"1990","unstructured":"Hochberg MC, Spector TD. Epidemiology of rheumatoid arthritis: update. Epidemiol Rev. 1990;12:247\u201352.","journal-title":"Epidemiol Rev"},{"key":"2170_CR6","doi-asserted-by":"publisher","first-page":"152747","DOI":"10.1016\/j.semarthrit.2025.152747","volume":"73","author":"D Kesibi","year":"2025","unstructured":"Kesibi D, et al. A cohort study on the associations between age at natural menopause and rheumatoid arthritis in postmenopausal women from the Canadian Longitudinal Study on Aging. Semin Arthritis Rheum. 2025;73:152747.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"2170_CR7","doi-asserted-by":"publisher","first-page":"Itc1","DOI":"10.7326\/AITC201901010","volume":"170","author":"JA Sparks","year":"2019","unstructured":"Sparks JA. Rheumatoid Arthritis. Ann Intern Med. 2019;170(1):Itc1-itc16.","journal-title":"Ann Intern Med"},{"issue":"12","key":"2170_CR8","doi-asserted-by":"publisher","first-page":"e15440","DOI":"10.1111\/1756-185X.15440","volume":"27","author":"CH Hung","year":"2024","unstructured":"Hung CH, Lu LY, Huo AP. Editorial: rheumatoid arthritis and chronic obstructive pulmonary disease: pathogenesis and treatment challenges. Int J Rheum Dis. 2024;27(12):e15440.","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"2170_CR9","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1186\/ar2404","volume":"10","author":"AL Smitten","year":"2008","unstructured":"Smitten AL, et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R45.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"2170_CR10","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924\u201339.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"2170_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1159\/000493390","volume":"27","author":"J Bullock","year":"2018","unstructured":"Bullock J, et al. Rheumatoid arthritis: a brief overview of the treatment. Med Princ Pract. 2018;27(6):501\u20137.","journal-title":"Med Princ Pract"},{"issue":"3","key":"2170_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S0950-3579(05)80002-0","volume":"4","author":"KD Rainsford","year":"1990","unstructured":"Rainsford KD. Disease-modifying antirheumatic and immunoregulatory agents. Baillieres Clin Rheumatol. 1990;4(3):405\u201332.","journal-title":"Baillieres Clin Rheumatol"},{"key":"2170_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154459","author":"F Wang","year":"2022","unstructured":"Wang F, et al. Efficacy and safety of JAK inhibitors for rheumatoid arthritis: a meta-analysis. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11154459.","journal-title":"J Clin Med"},{"issue":"4","key":"2170_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, et al. Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"issue":"10","key":"2170_CR15","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/art.42250","volume":"74","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, et al. Tofacitinib and risk of malignancy: results from the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) study. Arthritis Rheumatol. 2022;74(10):1648\u201359.","journal-title":"Arthritis Rheumatol"},{"key":"2170_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030390","author":"CB Driscoll","year":"2025","unstructured":"Driscoll CB, et al. Tumor necrosis factor-alpha inhibitor use and malignancy risk: a systematic review and patient level meta-analysis. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17030390.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2170_CR17","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1136\/ard-2023-224049","volume":"82","author":"MD Russell","year":"2023","unstructured":"Russell MD, et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis. 2023;82(8):1059\u201367.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2170_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semarthrit.2017.02.007","volume":"47","author":"JR Maneiro","year":"2017","unstructured":"Maneiro JR, Souto A, Gomez-Reino JJ. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: systematic review, meta-analysis, and network meta-analysis. Semin Arthritis Rheum. 2017;47(2):149\u201356.","journal-title":"Semin Arthritis Rheum"},{"key":"2170_CR19","doi-asserted-by":"publisher","first-page":"1403967","DOI":"10.3389\/fonc.2024.1403967","volume":"14","author":"K Chen","year":"2024","unstructured":"Chen K, et al. Comparative efficacy and hematologic safety of different dosages of JAK inhibitors in the treatment of myelofibrosis: a network meta-analysis. Front Oncol. 2024;14:1403967.","journal-title":"Front Oncol"},{"issue":"11","key":"2170_CR20","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","volume":"177","author":"H Wadstr\u00f6m","year":"2017","unstructured":"Wadstr\u00f6m H, Frisell T, Askling J. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, Tocilizumab, Abatacept, or Rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Intern Med. 2017;177(11):1605\u201312.","journal-title":"JAMA Intern Med"},{"issue":"12","key":"2170_CR21","first-page":"1457","volume":"22","author":"J Harnett","year":"2016","unstructured":"Harnett J, et al. Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. administrative claims database. J Manag Care Spec Pharm. 2016;22(12):1457\u201371.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"2170_CR22","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016;75(5):831\u201341.","journal-title":"Ann Rheum Dis"},{"key":"2170_CR23","doi-asserted-by":"publisher","first-page":"152240","DOI":"10.1016\/j.semarthrit.2023.152240","volume":"64","author":"TA Simon","year":"2024","unstructured":"Simon TA, et al. Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study. Semin Arthritis Rheum. 2024;64:152240.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"2170_CR24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/ard-2022-223636","volume":"82","author":"V Huss","year":"2023","unstructured":"Huss V, et al. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Ann Rheum Dis. 2023;82(7):911\u20139.","journal-title":"Ann Rheum Dis"},{"key":"2170_CR25","doi-asserted-by":"publisher","first-page":"e2023045","DOI":"10.4178\/epih.e2023045","volume":"45","author":"HK Min","year":"2023","unstructured":"Min HK, et al. Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data. Epidemiol Health. 2023;45:e2023045.","journal-title":"Epidemiol Health"},{"issue":"15","key":"2170_CR26","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008\u201312.","journal-title":"JAMA"},{"issue":"1","key":"2170_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12916-022-02419-9","volume":"20","author":"SC Shao","year":"2022","unstructured":"Shao SC, et al. Associations of thiazide use with skin cancers: a systematic review and meta-analysis. BMC Med. 2022;20(1):228.","journal-title":"BMC Med"},{"issue":"9","key":"2170_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"2170_CR29","unstructured":"Higgins JPT, et al., Cochrane Handbook for Systematic Reviews of Interventions version 6.4. 2023."},{"issue":"1","key":"2170_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","volume":"21","author":"MA Hern\u00e1n","year":"2010","unstructured":"Hern\u00e1n MA. The hazards of hazard ratios. Epidemiology. 2010;21(1):13\u20135.","journal-title":"Epidemiology"},{"key":"2170_CR31","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.","journal-title":"BMJ"},{"key":"2170_CR32","doi-asserted-by":"publisher","DOI":"10.4103\/ds.DS-D-22-00154","author":"S-C Shao","year":"2023","unstructured":"Shao S-C, et al. Using grading of recommendations assessment, development, and evaluation (GRADE) to rate the certainty of evidence of study outcomes from systematic reviews: a quick tutorial. Dermatol Sin. 2023. https:\/\/doi.org\/10.4103\/ds.DS-D-22-00154.","journal-title":"Dermatol Sin"},{"key":"2170_CR33","unstructured":"England BR, et al., Risk of Incident Cancer with Biologic and Tofacitinib Therapy in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol, 2016"},{"issue":"3","key":"2170_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/acr2.11232","volume":"3","author":"JM Kremer","year":"2021","unstructured":"Kremer JM, et al. Postapproval comparative safety study of Tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. ACR Open Rheumatol. 2021;3(3):173\u201384.","journal-title":"ACR Open Rheumatol"},{"issue":"2","key":"2170_CR35","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.semarthrit.2019.03.002","volume":"49","author":"SC Kim","year":"2019","unstructured":"Kim SC, et al. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multi-database cohort study. Semin Arthritis Rheum. 2019;49(2):222\u20138.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"2170_CR36","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1093\/rheumatology\/kead079","volume":"62","author":"T Uchida","year":"2023","unstructured":"Uchida T, et al. Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study. Rheumatology (Oxford). 2023;62(10):3358\u201365.","journal-title":"Rheumatology (Oxford)"},{"key":"2170_CR37","doi-asserted-by":"crossref","unstructured":"Mok, C.C., et al., Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry. Rheumatology (Oxford), 2023.","DOI":"10.1136\/annrheumdis-2023-eular.3391"},{"issue":"5","key":"2170_CR38","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.semarthrit.2020.08.007","volume":"50","author":"W Xie","year":"2020","unstructured":"Xie W, et al. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies. Semin Arthritis Rheum. 2020;50(5):930\u20137.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"2170_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11864-020-00815-y","volume":"22","author":"CS Greif","year":"2021","unstructured":"Greif CS, Srivastava D, Nijhawan RI. Janus kinase inhibitors and non-melanoma skin cancer. Curr Treat Options Oncol. 2021;22(2):11.","journal-title":"Curr Treat Options Oncol"},{"key":"2170_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082197","author":"C Bezzio","year":"2023","unstructured":"Bezzio C, et al. Cancer risk in patients treated with the JAK inhibitor tofacitinib: systematic review and meta-analysis. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15082197.","journal-title":"Cancers (Basel)"},{"key":"2170_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002614","author":"YJ Song","year":"2022","unstructured":"Song YJ, et al. Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study. RMD Open. 2022. https:\/\/doi.org\/10.1136\/rmdopen-2022-002614.","journal-title":"RMD Open"},{"issue":"2","key":"2170_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/BOR.0000000000000782","volume":"33","author":"K Yip","year":"2021","unstructured":"Yip K, Navarro-Mill\u00e1n I. Racial, ethnic, and healthcare disparities in rheumatoid arthritis. Curr Opin Rheumatol. 2021;33(2):117\u201321.","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"2170_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/rheumatology\/kead163","volume":"63","author":"R Westermann","year":"2024","unstructured":"Westermann R, et al. Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study. Rheumatology (Oxford). 2024;63(1):93\u2013102.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"2170_CR44","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/bcpt.12946","volume":"122","author":"A Potteg\u00e5rd","year":"2018","unstructured":"Potteg\u00e5rd A, et al. Considerations for pharmacoepidemiological studies of drug-cancer associations. Basic Clin Pharmacol Toxicol. 2018;122(5):451\u20139.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"2170_CR45","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12933-021-01406-3","volume":"20","author":"SC Shao","year":"2021","unstructured":"Shao SC, et al. Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease. Cardiovasc Diabetol. 2021;20(1):213.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02170-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-025-02170-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02170-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T13:45:45Z","timestamp":1767879945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-025-02170-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2170"],"URL":"https:\/\/doi.org\/10.1007\/s00011-025-02170-w","relation":{},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"15"}}